DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Biological: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: Therapeutic Tumor Infiltrating Lymphocytes

First Posted Date: 2013-03-08

Last Posted Date: 2022-11-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01807182

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Not Applicable

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Acute Biphenotypic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Drug: Liposomal Cytarabine-Daunorubicin CPX-351

First Posted Date: 2013-03-05

Last Posted Date: 2018-05-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 48

Registration Number: NCT01804101

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: HIV-associated Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Splenic Marginal Zone Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: melphalan
Drug: etoposide
Drug: O6-benzylguanine
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-01-17

Last Posted Date: 2015-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01769911

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Phase 1

Terminated

Conditions: Recurrent Merkel Cell Carcinoma
Stage IV Merkel Cell Carcinoma

Interventions: Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Radiation: Radiation Therapy
Biological: Recombinant Interferon Beta

First Posted Date: 2013-01-01

Last Posted Date: 2017-04-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01758458

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

Not Applicable

Completed

Conditions: Hematopoietic/Lymphoid Cancer

Interventions: Other: palliative care
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2013-01-01

Last Posted Date: 2016-03-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01758484

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Recurrent Adult Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Decitabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2012-11-20

Last Posted Date: 2019-02-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 52

Registration Number: NCT01729845

Locations: 🇺🇸
Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
EvergreenHealth Medical Center, Kirkland, Washington, United States

Glucosamine and Chondroitin Effects

Not Applicable

Completed

Conditions: Inflammation

Interventions: Dietary Supplement: Glucosamine and Chondroitin
Dietary Supplement: placebo

First Posted Date: 2012-09-11

Last Posted Date: 2014-05-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01682694

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Phase 1

Terminated

Conditions: Anaplastic Large Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Biological: indium In 111 anti-CD45 monoclonal antibody BC8
Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2012-09-05

Last Posted Date: 2021-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01678443

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Phase 1

Terminated

Conditions: Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Donor
Hematopoietic Cell Transplant Recipient
Recurrent Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
HLA-A*0201 Positive Cells Present

Interventions: Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Drug: Cyclophosphamide
Biological: WT1-Sensitized Allogeneic T-Lymphocytes
Drug: Fludarabine Phosphate

First Posted Date: 2012-07-13

Last Posted Date: 2022-07-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01640301

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1

Withdrawn

Conditions: Hematopoietic/Lymphoid Cancer

Interventions: Drug: brentuximab vedotin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2012-06-15

Last Posted Date: 2014-04-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01620229

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy